Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases.
With its world-class visionary pharmaceutical advisory team and global biologics development team, Biosion is committed to creating and delivering the next generation of innovative therapeutics with significant medical outcomes for patients worldwide.
To deliver breakthrough therapeutics to patients globally
Biosion is a Leading “In Global For Global” Biotech Company
Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year.
“With our global professional team and operations, we are passionate to deliver breakthrough medicines for patients worldwide through the synergy of robust innovative discovery, cutting-edge technologies and global collaborations.”